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Abstract A total of 14 patients with platinum-resistant 
advanced epithelial ovarian cancer were treated with a 
continuous infusion of high-dose 5-fluorouracil (5-FU, 
1200 mg/m2 per day) for 2 consecutive days weekly for 
4 weeks and, thereafter, every 2 weeks in combination with 
a push injection of folinic acid (20 mg/m2) given just before 
5-FU and after 24 h. No objective response was document­
ed, and only five patients showed stable disease. The 
median survival was 6.5 months. There was minimal 
toxicity. This schedule of 5-FU in combination with folinic 
acid is not effective as second-line chemotherapy in 
advanced ovarian cancer.
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Introduction
Standard treatment of ovarian cancer of FIGO stage III or 
IV consists of surgery followed by platinum-containing 
chemotherapy. This treatment results in a 7 0 -8 0 %  overall
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response rate and a 20% rate of 10-year survival, This 
means that most patients will suffer a relapse of their 
disease [3S 11]. Patients who have responded to initial 
therapy or have shown no progression for at least 
6 months should be offered platinum-containing chemo­
therapy again. On the other hand, if there is no regression 
on initial therapy or progression of the malignancy within 
6 months, second-line chemotherapy should be considered
[3, 11].
The results of second-line chemotherapy with, for 
example, ifosfamide, taxol, or hexamethylmelamine are 
poor due to the low response rates of 10-30%  [11]. 
5-Fluorouracil (5-FU) is effective in ovarian cancer [1], 
5-FU inhibits DNA synthesis by interaction with the 
enzyme thymidylate synthetase. Leucovorin (folinic acid) 
stabilizes this complex [8], thereby enhancing the effect of 
5-FU, as has been shown in colorectal cancer [9], Platinum 
resistance is thought to be caused by a mechanism other 
than the mode of action of 5-FU and leucovorin [4]. 
Recently, Lou vet et al. [7] reported the results obtained 
using 5-FU and leucovorin in the treatment of patients with 
cisplatin-resistant ovarian cancer. They found a response 
rate of 19% and a median survival of 9 months. Toxicity 
was minimal [7]. Herein we report the results of treatment 
with high-dose 5-FU in combination with leucovorin in 
similar patients with platinum-resistant ovarian cancer.
Patients and methods
In the period ranging from March 1990 until May 1993, 14 patients 
(mean age, 59.5 years; range, 45-73  years) participated in this study 
after giving their informed consent. They had epithelial ovarian cancer 
of FIGO stage III or IV, and the tumor either was progressive despite 
previous platinum-containing chemotherapy or relapsed within
6 months after completion of the last platinum-containing regimen. 
Treatment consisted of a continuous infusion of 5-FU (1200 mg/m2 per 
day over 2 days) given weekly for 4 weeks and, thereafter, every
2 weeks. Leucovorin (20-mg/m3 push dose) was given intravenously 
just before the 5-FU infusion and after 24 h. Evaluation was scheduled 
after six courses unless there was major toxicity or clear progression
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Table 1 Patients’ characteristics and results (CR complete remission, PR partial remission, NC no change, PD progressive disease
Patient
number
Age
(years)
Stage
(FIGO)
Previous 
chemoa 
(response)
Interval0
(months)
PS‘ Courses
(/?)
Response11 CA-125e Time Survival 
to PD (months) 
(months)
1 66 IIIB PC-7(PR) 12 1 11 NCr i r 4 6
2 73 IV PC-6(NC) 7 1 11 PD t 2 8
3 48 IV PC-6(PR) 
CC- 3 (PR) 
CAP-1 (NE)
15 1 5 ePD NE 3 5
4 70 me CC-3(PD) 11 2 4 ePD 1 3
5 64 IIIB PC-6(CR) 12 0 6 PD 2 20
6 60 me PC-7(PD) 9 1 5 ePD Î 2 5
7 61 me CC-6(PR) 10 1 8 NC 3 5
8 55 m e PC-6(PR) 11 0 7 PD î 2 7
9 55 m e CEP-9(PR) 
C1-6 (PR)
42 1 15 NC 8 23
10 59 m e CHAC~9(CR) 
CC-6(CR) 
PC-6(PR) 
CEP-2 (PD)
77 1 12 NC NE 6 16
11 58 IV PC-9(CR)
CC-6(PD)
31 2 4 ePD Î 1 3
12 45 IV PC-7(CR)
CC-2(CR)
16 0 7 PD Î 2 18
13 68 me PC-1
CC-5(PR)
CC~2(PD)
9 1 4 ePD T 1 2
14 51 m e PC-5(PD) 
HORM(PD) 
TAX-2 (NC) 
MEL-l(PD)
18 1 12 NC <—> 5 10
a Chemotherapy -  numbers represent the number of courses received: 
PC, cisplatin/cyclophosphamide; CC, carboplatin/cyclophosphamide; 
CHAC, cyclophosphamide/hexamethylrnelamine/Adriamycin/carbo- 
platin; Cl, carboplatin/ifosfamide; CAP, cyclophosphamide/Adriamy- 
cin/cisplatin; CEP, cyclophosphamide/etoposide/cisplatin; HORM, 
hormonal treatment; MEL, melphalan; TAX, taxotere 
b Interval from diagnosis until the start of second-line chemotherapy 
c Performance status according to the Eastern Cooperative Oncology 
Group at the start of protocol treatment
d ePD, Early progressive disease; progression within 6 courses 
independently of time. Response based on CT scan and/or CA-125 
levels measured after 6 (or fewer) courses
e CA-125 levels measured after 6 courses or earlier if fewer courses 
were given: >25%  increase; J, > 5 0 %  decrease; «-►, between 50% 
decrease and 25% increase; NE, not evaluable or measured 
f In patient 1, CA-125 levels decreased by more than 50% but 
increased shortly afterwards; this is considered no change
during the chemotherapy. Response was measured by computerized 
tomography (CT) and/or by CA-125 levels.
Results
The patients5 characteristics and results are summarized in 
Table 1. In all, 4 patients showed progression during the 
first-line platinum-containing chemotherapy, 2 were pro­
gressive following platinum-containing regimens, and 6 had 
a recurrence within 6 months. Altogether, 2 patients were 
not eligible; 1 received more modes of (chemo)therapy 
(patient 14), and the other was free of disease for more 
than 6 months (patient 12). These patients were also 
evaluated.
An average of 8 courses of 5-FU and leucovorin were 
given (range, 4 - 1 5  courses); 5 patients received fewer than 
6 courses because of early progression (4 cases) and 
worsening of the clinical condition (1 case). CA-125 levels 
decreased by > 5 0 %  only very briefly in 1 patient and 
remained stable in 5 patients. CT scanning showed no 
change in 3 patients and progression in 7. In all, 1 patient 
was evaluated by X-ray of the chest (progression), 1 was 
evaluated by ultrasound (stable disease), and 2 patients 
were not evaluated with roentgenological investigations (no 
measurable disease).
Overall, stable disease was reported in 5 cases and 
progression, in 9, The median time to progression was
2 months (mean 3 months), and the median survival was
6.5 months (mean, 9.4 months). Altogether, 4 patients 
survived for more than 1 year; 3 of them received addi-
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tional chemotherapy, radiotherapy, and/or hormonal ther­
apy. Finally, all patients developed progressive disease and 
died.
Side effects were acceptable, involving nausea or vom­
iting in 9 patients [3 cases being severe (WHO grade 3)] 
and diarrhea in 6 (2 cases being severe). Neurological side 
effects (in 2 patients), stomatitis (3 cases), alopecia (1 case), 
and hand-foot syndrome (2 cases) were reported inciden- 
' tally. There was no major hematological toxicity.
Discussion
Second-line treatment in platinum-resistant ovarian cancer 
is troublesome. Agents that are not cross-resistant are 
sought, but only low response rates and short periods of 
median survival have been reported. Such agents include 
taxol (response, 24 -30% ; median duration of response, 
4 months), ifosfamide (response, 12%) and, maybe, hexa- 
methylmelamine (response anecdotal) [11].
The mode of action of 5-FU is thought to be different 
from that of platinum-containing compounds [4]. This 
makes the combination of 5-FU and leucovorin an inter­
esting option for patients with platinum-resistant ovarian 
cancer. In our study, no objective response was document­
ed; 5 patients had stable disease and 9 showed progression.
This outcome, i. e., no response and a median survival of
6.5 months, is worse than the results reported by Louvet et 
al. [7]. In 16 evaluable patients they obtained 1 complete 
response and 2 partial responses. The median survival was 
9 months. These investigators gave a lower dose of 5-FU 
(1000 mg/m2 per day given for 2 days every 2 weeks), 
albeit partly as a push injection (400 mg/m2). In our study 
we infused 5-FU continuously (1200 mg/m2 per day for
2 days) weekly for 4 weeks and, thereafter, every 2 weeks. 
The dose of leucovorin used by Louvet et al. [7] was 10- 
fold that given by us.
In colorectal cancer, numerous schedules for 5-FU and 
leucovorin have been evaluated, but the best regimen is not 
known. A combination of 5-FU and leucovorin provides 
better results than does 5-FU alone [6, 9]. One study 
suggests that a combination regimen involving continuous 
infusion of 5-FU is superior to bolus treatment with 5-FU 
[10], but another investigation shows no difference [2], A 
nonrandomized study in which 5-FU was given as a bolus 
and by continuous infusion in combination with leucovorin 
to 37 patients revealed a higher response rate and a longer
median survival than those reported for former regimens 
[5]. Therefore, the push injection of 5-FU in combination 
with continuous infusion might explain the observed 
difference in outcome between our study and that of 
Louvet et al. [7]. The dose of leucovorin is probably of 
less importance since high and low doses are equally 
effective in colorectal cancer [9]. Another difference 
might be that the patients in the present study had been 
more heavily pretreated. We conclude this regimen given at 
the dose and dose schedule used in our study is not effective 
as second-line treatment in platinum-resistant ovarian 
cancer.
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